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OBJECTIVE
Sodium–glucose cotransporter (SGLT)-2 inhibitors lower clinic and ambulatory
blood pressure (BP), possibly through their natriuretic action. However, it remains
unclear whether this BP-lowering effect is dose dependent and different from that
of low-dose hydrochlorothiazide. The purpose of thismeta-analysis was to quantify
the association of the dosewith response of ambulatory BP to SGLT-2 inhibition and
to provide comparative evaluation with low-dose hydrochlorothiazide.
RESEARCH DESIGN AND METHODS
PubMed/MEDLINE, Embase, and Cochrane database of clinical trials from inception
of each database through 22 August 2018. Randomized controlled trials (RCTs)
reporting treatment effects of SGLT-2 inhibitors on ambulatory BP. We extracted
data on the mean difference between the active treatment and placebo groups in
change from baseline (CFB) of ambulatory systolic and diastolic BP.
RESULTS
We identified seven RCTs (involving 2,381 participants) comparing SGLT-2 inhibitors
with placebo. Of these, two RCTs included low-dose hydrochlorothiazide as active
comparator. CFB in 24-h systolic BP between SGLT-2 inhibitor and placebo groups
was23.62mmHg (95% CI24.29,22.94) and in diastolic BPwas21.70mmHg (95%
CI 22.13, 21.26). BP lowering with SGLT-2 inhibition was more potent during
daytime thanduring nighttime. TheCFB in ambulatory BPwas comparable between
low-dose and high-dose subgroups and was similar to that for low-dose hydro-
chlorothiazide. Eligible RCTs did not evaluate cardiovascular outcomes/mortality.
CONCLUSIONS
This meta-analysis shows that SGLT-2 inhibitors provoke an average reduction of
systolic/diastolic BP 3.62/1.70 mmHg in 24-h ambulatory BP. This BP-lowering effect
remains unmodified regardless of the dose of SGLT-2 inhibitor and is comparable
with BP-lowering efficacy of low-dose hydrochlorothiazide.
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Worldwide, diabetes is a major cause of
increased burden of cardiovascular mor-
bidity andmortality. Recently, a new class
of drugs, the sodium–glucose cotransporter
(SGLT)-2 inhibitors, have been used to
treat patients with type 2 diabetes (1).
These trials show that SGLT-2 inhibitors
may confer cardiovascular protection,
including a reduction in cardiovascular
death (2,3). Furthermore, these trials
also demonstrate a reduced risk of hospi-
talization due to heart failure (2,3). One
mechanism that may account for cardio-
vascular benefit of this class of drugs
appears to be through blood pressure
(BP) reduction (1). Prior studies have
shown that reducing BP can reduce car-
diovascular morbidity and mortality (4).
Furthermore, BP reduction has a pro-
found effect on reduction in heart failure
hospitalization (4,5). In clinical trials, BP
reduction is often measured in the clinic.
However, ambulatory BP monitoring
(ABPM) has emerged as a more reliable
measure to predict adverse cardiovascu-
lar events (6).
In this meta-analysis, we ask the fol-
lowing questions: 1) whether approved
SGLT-2 inhibitors in the U.S. can improve
ambulatory BP over 24 h, during daytime,
and during night; 2) whether the dose of
the SGLT-2 inhibitor is related to an im-
provement in BP; and 3) whether the
BP-lowering effects of SGLT-2 inhibitors
are similar to that seen with hydrochloro-
thiazide. We reasoned that if these drugs
simply improved BP similar to improve-
ment seen with hydrochlorothiazide, then
the cardiovascular benefits of SGLT-2 in-
hibitors may extend beyond BP lowering.
A prior meta-analysis has already ex-
amined the mean reduction in 24-h am-
bulatory BP and reported it as 3.76 mmHg
systolic reduction and 1.83 mmHg dias-
tolic reduction compared with placebo
(7). However, the two questions that we
posedthe dose-response relationship
and the comparison of the results with
hydrochlorothiazidedwere not exam-
ined in the priormeta-analysis. Therefore,
besides updating the prior meta-analysis,
our study provides answers to questions
that are relevant and timely.
RESEARCH DESIGN AND METHODS
Literature Search and Selection of
Trials
To identify randomized controlled trials
(RCTs) evaluating the effect of SGLT-2
inhibitors on ambulatory BP, we per-
formed a systematic literature search
of PubMed/MEDLINE, Embase, and
Cochrane database of clinical trials
using a structured search strategy re-
ported in Supplementary Table 1. Litera-
ture search had no language restrictions
and was carried out from inception of
each database through 22 August 2018.
Reference lists of articles retrieved for
detailed evaluation, relevant review arti-
cles, and earlier meta-analyses were
also examined to identify additional stud-
ies for potential inclusion in this quanti-
tative review.
Suitability of each identified article
for inclusion was independently adjudi-
cated by two authors using prespecified
selection criteria. Disagreements be-
tween authors were resolved by con-
sensus. We included RCTs with a
follow-up of at least 4 weeks enrolling
adult patients with diabetes, in which the
BP-lowering effect of SGLT-2 inhibitors
was compared with placebo or active
therapy with other antidiabetes medica-
tions and/or hydrochlorothiazide. To be
eligible, the study had to report treat-
ment effects on 24-h ambulatory BP in a
manner suitable for quantitative data
synthesis.
Data Extraction and Study Quality
Assessment
A purpose-built data collection form was
used to extract the following character-
istics of each eligible study: study design,
participant characteristics (age, sex, base-
line levels of clinic and 24-h ambulatory
BP, hypertension status, and background
therapy with antihypertensive medica-
tions), therapeutic interventions (type
of SGLT-2 inhibitor, dose, and back-
ground therapy with antidiabetes med-
ications or insulin), duration of follow-up,
comparison groups, and outcomes of
interest. All data were extracted inde-
pendently by two investigators and
were confirmed for accuracy by the
primary investigator (R.A.).
The method quality of each eligible
study was assessed by two authors in-
dependently using the Risk of Bias (RoB)
2.0 tool (8). This tool includes a descrip-
tion and a judgment in a table that
addresses specific sources of bias for
every study, including the following:
bias arising from the randomization
process, bias due to deviations from
intended intervention, bias due to
missing outcome data, bias in measure-
ment of the outcome, and bias in se-
lection of the reported result (8).
Statistical Analysis
We used a fixed-effects model to esti-
mate the weighted mean difference be-
tween the active treatment and placebo
groups in change from baseline (CFB) of
ambulatory systolic and diastolic BP. We
provide effect estimates separately for
24-h, daytime, and nighttime periods.
We used the I2 statistic in order to
quantify statistical heterogeneity among
individual studies. For exploration of
potential interactions between the
dose and response of ambulatory BP
to therapy, eligible RCTs were stratified
according to the dose of SGLT-2 inhibitor
(lowversus high dose). Specifically, treat-
ment arms of individual RCTs with the
highest recommended daily dose for
each SGLT-2 inhibitor (i.e., canagliflozin
300 mg/day, dapagliflozin 10 mg/day,
empagliflozin 25 mg/day, and ertugli-
flozin 25 mg/day) were stratified in the
high-dose subgroup. All other treat-
ment arms using a dose lower than
the highest recommended dose were
combined in the low-dose subgroup.
For comparison of the BP-lowering
effect of SGLT-2 inhibitors with that of
low-dose hydrochlorothiazide, eligible
RCTs were stratified according to active
treatment (SGLT-2 inhibitor versus low-
dose hydrochlorothiazide). To explore
the association of baseline ambulatory
BP with the reduction in ambulatory BP
provoked by SGLT-2 inhibitors, we per-
formed random-effects meta-regression
analysis. All analyses were performed
using the metan and metareg com-
mands in Stata 14.2 (StataCorp LLC,
College Station, TX).
RESULTS
Trial Flow and Study Characteristics
The literature search and flowdiagramof
study selection are depicted in Fig. 1. Of
the 289 studies initially identified and
screened, 64 studies were considered
potentially relevant and were retrieved
fordetailedevaluation.Of these, 57 stud-
ies were excluded for the following rea-
sons: no use of ABPM in assessment of
the BP-lowering effect of SGLT-2 inhib-
itors (n = 46), absence of randomization
(n = 8), protocol of an ongoing trial (n =
1), and duplicate publication (n = 2). A
total of seven RCTs, enrolling 2,381
694 SGLT-2 Inhibitors and Ambulatory BP Reduction Diabetes Care Volume 42, April 2019
adult participants with type 2 diabetes,
were finally included in quantitative
data synthesis (9–15).
As shown in Table 1, of the seven
double-blind, placebo-controlled RCTs
included, six followed a parallel-group
assignment (9,11–15) and one followed
a crossover design (10). Of these, four
studies used dapagliflozin adminis-
tered at a single dose of 10 mg/day
(10,11,14,15), one study used empagli-
flozin administered at doses of 10 and
25 mg/day (12), one study used canagli-
flozin at doses of 100 and 300 mg/day
(13), and one study used ertugliflozin at
doses ranging from 1 to 25 mg/day (9).
In two of seven studies, low-dose hy-
drochlorothiazide (12.5–25 mg/day) was
used as active comparator (9,11). The
number of participants randomly as-
signed to SGLT-2 inhibitor therapy
ranged from 24 to 302, the number
of placebo-treated participants ranged
from 25 to 311, and the number of
participants randomized to low-dose hy-
drochlorothiazide ranged from 26 to 39.
Duration of follow-up ranged from 4 to
12 weeks. Additional data on background
antihypertensive therapy are depicted in
Supplementary Table 3. Background an-
tihypertensive therapy was continued
during follow-up in six out of seven eligible
RCTs (9,11–15), but modifications in the
intensity of therapy were prohibited by
protocol on all occasions.
Method quality was assessed for all
studies using the RoB 2.0 tool (Supple-
mentary Table 2); no studies were ex-
cluded as a result of suboptimal method
quality.
Effect on 24-h Ambulatory Systolic
and Diastolic BP
We identified seven RCTs (9–15) that
compared SGLT-2 inhibitorswithplacebo
and reported data on 24-h systolic BP.
CFB in 24-h systolic BP between the
SGLT-2 inhibitors and placebo was23.62
mmHg (95% CI 24.23, 22.94) (Fig. 2)
and for 24-h diastolic BP, reported in five
RCTs (9,10,12–14), was 21.70 mmHg
(95% CI 22.13, 21.26) (Fig. 3). There
was no evidence of heterogeneity across
studies with respect to both 24-h systo-
lic BP (I2 = 0, P = 0.936) and diastolic BP
(I2 = 0, P = 0.435).
As shown in Fig. 4, for exploration of
potential dose-response associations,
RCTs were stratified by dose of SGLT-2
inhibitor. In the low-dose subgroup, CFB
in 24-h systolic BP between SGLT-2 in-
hibitors and placebo differed by 23.50-
mmHg (95% CI 24.67, 22.32); in the
high-dose subgroup, the difference
was 23.73 mmHg (95% CI 24.57,
22.88). There was no evidence of
heterogeneity between subgroups (P =
0.756). In the low-dose subgroup, CFB in
24-h diastolic BP between SGLT-2 inhib-
itors and placebowas21.62mmHg (95%
CI 22.32, 20.91); in the high-dose sub-
group, it was 21.67 mmHg (95% CI
22.25, 21.10). Once again, no hetero-
geneity between subgroups was evident
(P = 0.903) (Supplementary Figs. 1 and
2 for forest plots).
For comparison of the BP-lowering
effect of SGLT-2 inhibitors with that of
low-dose hydrochlorothiazide, RCTs were
stratified by active treatment. CFB in 24-h
systolic BP between the SGLT-2 inhibitors
and placebo was 23.62 mmHg (95%
CI24.29,22.94) and for low-dose hydro-
chlorothiazide was 23.46 mmHg (95%
CI 26.15, 20.77). CFB in 24-h diastolic
BP averaged 21.70 mmHg (95% CI
22.13, 21.26) for SGLT-2 inhibitor and
22.23 mmHg (95% CI 24.34, 20.12) for
low-dose hydrochlorothiazide (Fig. 4).
Thus, the BP-lowering effect of SGLT-2
inhibitors was comparable with that of
low-dose hydrochlorothiazide (see Sup-
plementary Figs. 3 and 4 for forest
plots).
In meta-regression analysis, 24-h sys-
tolic and diastolic BP at baseline had
no association with the reduction in
24-h BP provoked by SGLT-2 inhibitors
(see Supplementary Figs. 17 and 18).
Effect on Daytime Systolic and
Diastolic BP
CFB in daytime systolic BP between the
SGLT-2 inhibitors and placebo was re-
ported in six RCTs (9,11–15) and
averaged 24.32 mmHg (95% CI 25.06,
23.57). CFB in daytime diastolic BP be-
tween the SGLT-2 inhibitors and placebo
was reported in four RCTs (9,12,13,15)
and averaged22.03 mmHg (95% CI22.53,
21.53). When the analysis was stratified
by low versus high SGLT-2 inhibitor dose,
no significant interaction between the
dose and response of daytime systolic
and diastolic BP to SGLT inhibitor therapy
was evident. When the analysis was
stratified according to the type of active
comparator, the magnitude of decrease
in daytime systolic and diastolic BP rel-
ative to placebowas similar in the SGLT-2
and low-dose hydrochlorothiazide sub-
groups (Fig. 4) (see Supplementary Figs.
5–10 for forest plots).
Random-effects meta-regression showed
no association of daytime systolic and
diastolic BP at baseline with the reduction
Figure 1—Flow diagram of studies considered for inclusion. DM, diabetes.
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in daytime BP provoked by SGLT-2 in-
hibitors (see Supplementary Figs. 19
and 20).
Effect on Nighttime Systolic and
Diastolic BP
CFB in nighttime systolic BP between
the SGLT-2 inhibitors and placebo was
reported in six RCTs (9,11–15) and
averaged 22.62 mmHg (95% CI
23.46,21.78). CFB in nighttimediastolic
BP between the SGLT-2 inhibitors and
placebo was reported in four RCTs
(9,12,13,15) and averaged 21.39 mmHg
(95% CI 21.96, 20.81). Analyses strat-
ified by dose of SGLT-2 inhibitors re-
vealed similar CFB in nighttime systolic
and diastolic BP between low-dose and
high-dose SGLT-2 inhibitors, indicating
absence of dose-response relationship
(Fig. 4). The magnitude of decrease in
nighttime systolic and diastolic BP rela-
tive to placebo did not differ between
the SGLT-2 and low-dose hydrochloro-
thiazide subgroups (see Supplementary
Figs. 11–16 for forest plots).
Random-effects meta-regression showed
no association of nighttime systolic and
diastolic BP at baseline with the re-
duction in nighttime BP provoked by
SGLT-2 inhibitors (see Supplementary
Figs. 21 and 22).
CONCLUSIONS
This systematic reviewandmeta-analysis
aimed to explore the BP-lowering action
of SGLT-2 inhibitors by combining RCTs
reporting treatment-induced changes
in ambulatory BP. The effect of these
agents on clinic BP was quantified in a
2017 meta-analysis of 43 RCTs (16) in
which SGLT-2 inhibitors provoked an
average systolic/diastolic BP reduction
of 2.4/1.46 mmHg relative to placebo. A
subsequent meta-analysis of six RCTs
(involving 2,098 participants) showed
that compared with placebo, SGLT-2 in-
hibitors lowered 24-h BP by 3.76/
1.83 mmHg (7). Despite the fact that
our updated literature search led to
the identification of only one additional
ABPM trial, this study expands the results
of prior meta-analyses providing the
following findings: 1) compared with
placebo, SGLT-2 inhibitors lowered
24-h BP by 3.62/1.70 mmHg, a BP-
lowering action that was more potent
during daytime than during nighttime; 2)
the magnitude of ambulatory BP reduc-
tion was similar regardless of the dose of
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SGLT-2 inhibitor, suggesting a rather flat
dose-response relationship; 3) the mag-
nitude of ambulatory BP reduction with
SGLT-2 inhibition was comparable with
the BP-lowering effect of low-dose hy-
drochlorothiazide; and 4) ambulatory
BP at baseline had no association with
the treatment-induced reduction in
ambulatory BP.
Two large randomized trials designed
to test the cardiovascular safety of SGLT-
2 inhibitors provided evidence in favor
of a cardioprotective action of this drug
class. In the BI 10773 (Empagliflozin)
Cardiovascular Outcome Event Trial in
Type 2 Diabetes Mellitus Patients (EMPA-
REG OUTCOME) trial (3), compared with
placebo, empagliflozin lowered by 32%,
38%, and 35% the risk of all-cause
mortality, cardiovascular mortality, and
hospitalization due to worsening heart
failure, respectively (3). Similarly, in the
CANagliflozin cardioVascular Assess-
ment Study (CANVAS) Program (2), can-
agliflozin lowered by 14% the risk of
cardiovascular death and by 33% the
risk of heart failure hospitalization rela-
tive to placebo (2). The extent to which
this cardiovascular risk reduction is me-
diated through the BP-lowering action
of SGLT-2 inhibitors is an issue of sub-
stantial controversy. If this BP-lowering
effect is similar to that of low-dose
hydrochlorothiazide, as is evident in
the present meta-analysis, then the hy-
pothesis of a BP-mediated cardiovascular
benefit of these agents appears to be a
less likely explanation. Meta-analyses of
RCTs showed that monotherapy with
low-dose hydrochlorothiazide is inferior
to monotherapy with all other antihy-
pertensive drug categories in reducing
ambulatory BP (17). Notably, a benefit of
monotherapy with low-dose hydrochlo-
rothiazide on cardiovascular outcomes is
not supported by “hard” clinical trial
evidence. In addition, the overall cardio-
vascular risk reduction offered by diu-
reticsdas class effectdmay be not
applicable to low-dose hydrochlorothia-
zide owing to its less potent natriuretic
and BP-lowering action (18,19). Meta-
regression analysis of 123 studies (incor-
porating data from 613,815 participants)
showed that the relative risk reduction
in major cardiovascular outcomes is
proportional to the treatment-induced
reduction in BP levels (20). Accordingly,
an average reduction of 3.62/1.70mmHg
in 24-h BP with SGLT-2 inhibitors, seen in
the present meta-analysis, can only par-
tially explain the results of the EMPA-REG
OUTCOME trial and CANVAS. If BP low-
ering was the prominent mediator of
cardiovascular risk reduction, then an
improvement in atherosclerotic cardio-
vascular events also should have oc-
curred. In contrast, no such benefit on
the risk of nonfatal myocardial infarction
or stroke was evident in these trials (2,3).
The exact mechanisms responsible for
the BP-lowering action of SGLT-2 inhib-
itors still remain elusive. Contraction in
plasma volume mediated through natri-
uresis suggests a diuretic-like BP-lowering
effect of SGLT-2 inhibitors (1,21). How-
ever, SGLT-2 inhibitors differ from thia-
zides in that they have a relatively flat
dose-response relationship. In a 2011
dose-response meta-analysis including
11 RCTs using low-dose (12.5–25 mg/
day) and 5 RCTs using high-dose (50 mg/
day) hydrochlorothiazide, the CFB in
24-h BP averaged 26.5/24.5 mmHg
Figure 2—Forest plot depicting the CFB in 24-h ambulatory systolic BP (SBP) in the SGLT-2 group minus CFB in the placebo group. Blood Pr: Weber
et al. (14); Lancet DE: Weber et al. (15). BL, baseline; CANA, canagliflozin; DAPA, dapagliflozin; EMPA, empagliflozin; ERTU, ertugliflozin; ES, effect
size; PLC, placebo.
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with low-dose hydrochlorothiazide (17);
however, the CFB in 24-h BP was212.0/
25.4 mmHg with high-dose hydro-
chlorothiazide (17). A dose-dependent
BP-lowering action of hydrochlorothia-
zide is also supported by a 2014 Coch-
rane meta-analysis of 33 RCTs (22), in
which the placebo-subtracted CFB in
clinic BP with hydrochlorothiazide doses
of 6.25, 12.5, 25, and 50mg/daywas24/
22 mmHg, 26/23 mmHg, 28/23
mmHg, and 211/25 mmHg, respec-
tively (22).
Both SGLT-2 inhibitors and hydrochlo-
rothiazide have a greater effect on day-
time rather than nighttime BP. It is
thought that SGLT-2 inhibitors have an
attenuated glycosuric/natriuretic effect
at night (1). Among patients with stage
I hypertension, low-dose hydrochlo-
rothiazide (12.5 mg/day) was inferior
to chlorothalidone (6.25 mg/day) in low-
ering nighttime BP (23). By contrast,
extended-release formulation hydro-
chlorothiazide was equally effective
with chlorothalidone in improving
nocturnal hypertension (23). Given
that the cardiovascular protective ef-
fects of SGLT-2 inhibitors surpassed
even chlorothalidone, the salutary
effects cannot be attributed to BP
reduction or the patterns of BP re-
duction per se.
Several non–BP-lowering benefits of
SLGT-2 inhibitors have been proposed.
Randomized trials have shown that SGLT-
2 inhibitors reduce aortic pulse wave
velocity and other measures of arterial
stiffness (24,25), generating the hypo-
thesis that improvement in arterial
stiffness may be another plausible mech-
anistic explanation for cardiovascular
benefit. Long-term weight loss and im-
provement in body fat distribution are
proposed as additional pathways (26).
Notably, clinical data dissociate long-
term weight reduction with BP lowering,
suggesting that only the initial weight
lossdthat is mediated through plasma
volume contractiondmay partially ex-
plain the BP-lowering effect of SGLT-2
inhibitors (1,21,27). Suppression of the
renin-angiotensin-aldosterone and sym-
pathetic nervous systems and improve-
ment in nitric oxide bioactivity are less
likely mechanistic explanations for car-
diovascular protection in light of stud-
ies showing that these neuro-hormonal
pathways remain unchanged in response
to SGLT-2 inhibition (1,24,27).
This study has strengths and limita-
tions. A strength of this study is that its
design prespecified comparative analysis
of included RCTs stratified by the dose of
SGLT-2 inhibitor and type of active treat-
ment. Accordingly, this meta-analysis not
only updates but also expands the re-
sults of prior meta-analyses, providing
novel data on the dose-response rela-
tionship of SGLT-2 inhibitors with am-
bulatory BP reduction as well as
comparison of the BP-lowering effect
of SGLT-2 inhibitors with low-dose hy-
drochlorothiazide. However, this study
also has some limitations that need to be
acknowledged. As commonly occurring
in any quantitative review, RCTs com-
bined in this meta-analysis differed in
terms of design, participant character-
istics, duration of follow-up, type of
active treatment, and intensity of back-
ground antidiabetes and antihyperten-
sive therapy. We have reasons to
believe that these unavoidable differ-
ences across individual RCTs have not
influenced the strength of our findings
in the absence of statistically significant
Figure 3—Forest plot depicting the CFB in 24-h ambulatory diastolic BP (DBP) in the SGLT-2 group minus CFB in the placebo group. Blood Pr: Weber
et al. (14). BL, baseline; CANA, canagliflozin; DAPA, dapagliflozin; EMPA, empagliflozin; ERTU, ertugliflozin; ES, effect size; PLC, placebo.
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heterogeneity in quantitative data syn-
thesis. Another possible limitation is
that eligible RCTs did not examine the
effect of SGLT-2 inhibitors on cardio-
vascular outcomes and mortality. Ac-
cordingly, the association of BP lowering
with the cardiovascular risk reduction
offered by SGLT-2 inhibitors cannot be
quantified in this meta-analysis.
In conclusion, this meta-analysis
shows that among patients with type
2 diabetes, SGLT-2 inhibitors provoke an
average reduction of 3.62/1.70 mmHg in
24-h ambulatory BP. This BP-lowering
effect is more potent during daytime
than during nighttime and is not modified
by the dose of SGLT-2 inhibitor. Impor-
tantly, the effect of SGLT-2 inhibitors
on ambulatory BP is comparable with
that of low-dose hydrochlorothiazide. If
BP-lowering efficacy of these two drug
categories is truly equal, BP lowering
per se only partially explains the impres-
sive cardioprotective action demon-
strated in large-scale outcome trials
testing the cardiovascular safety of
SGLT-2 inhibitors.
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